Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to B...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cell Death Dis
Main Authors: Khamari, Raeeka, Trinh, Anne, Gabert, Pierre Elliott, Corazao-Rozas, Paola, Riveros-Cruz, Samuel, Balayssac, Stephane, Malet-Martino, Myriam, Dekiouk, Salim, Joncquel Chevalier Curt, Marie, Maboudou, Patrice, Garçon, Guillaume, Ravasi, Laura, Guerreschi, Pierre, Mortier, Laurent, Quesnel, Bruno, Marchetti, Philippe, Kluza, Jerome
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5832419/
https://ncbi.nlm.nih.gov/pubmed/29487283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0340-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍